Amatuximab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | mesothelin |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
Chemical and physical data | |
Formula | C6394H9870N1694O2024S46 |
Molar mass | 144.33 kg/mol (peptide) g·mol−1 |
(what is this?) (verify) |
Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.[1]
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009. [citation needed]
References
- Anti-mesothelin monoclonal antibody MORAb-009 entry in the public domain NCI Dictionary of Cancer Terms